<?xml version="1.0" encoding="UTF-8"?>
<p>However, we were aware that anticancer drugs often have low efficiency in the treatment and cure of cancer due to the acquired or intrinsic resistance of tumor cells to these agents [
 <xref rid="B160-molecules-26-00431" ref-type="bibr">160</xref>]. Indeed, resistance to one drug often implies resistance to a series of different drugs, which are structural and functionally very distinct, the designated multiple drugs resistance (MDR) [
 <xref rid="B160-molecules-26-00431" ref-type="bibr">160</xref>]. The MDR is heterogeneous, involving a combination of mechanisms, such as alteration of membrane transports [
 <xref rid="B160-molecules-26-00431" ref-type="bibr">160</xref>]. P-glycoprotein (P-gp) or ABCB1 is the best characterized efflux pump implicated in MDR [
 <xref rid="B161-molecules-26-00431" ref-type="bibr">161</xref>].
</p>
